Research on Hyperthermia
for Cancer Treatment
EVIDENCE LEVEL 1A
3 year disease free survival rate more than doubled when hyperthermia was combined with chemoradiation for locally advanced cervical cancer patients in South Africa (HR:0.65; [95%CI]:0.45-0.96; p=0.029), and with no additional side effects.
(C Mienaar 2022)
EVIDENCE LEVEL 1B
Regional Hyperthermia added to chemotherapy doubles the length of overall survival in patients with high-risk localised soft tissue sarcoma, and increases the median over-all survival from 6.2 years (CT) to 15.4 years when combined with Hyperthermia
(CT + HT).
EVIDENCE LEVEL 1B
Hyperthermia significantly improves relief of painful bone metastases increasing the 3 month complete response from 7.1% in radiotherapy alone to 37.9% in the combination group. Almost double the amount of patients achieved a zero pain score (BIP) in the HT + RT group; with pain relief lasting 3x longer.
(Chi et al, 2018)
EVIDENCE LEVEL 1A
Complete Response rate improved from 38.1% with radiotherapy alone, to 60.2% when combined with hyperthermia for locoregional recurrence breast cancer, and a 72% complete response rate for localised chest wall recurrence
RT + HT.
(Datta 2016, Meta-analysis)
EVIDENCE LEVEL 1A
A complete response (CR) was seen in 62,5% of all patients combining radiotherapy (RT) with Hyperthermia Vs 39,6% when RT was used alone. Hyperthermia along with radiotherapy enhances the likelihood of CR in HNCs by around 25% compared to radiotherapy alone with no significant additional acute or late morbidities.
(Datta 2015, Meta-analysis)
Contact Us
Please fill up the contact form to request more information, or schedule a consultation with us.
Phone
+27 21 205 0590
+44 20 7467 8300
Address
The Foundry, Prestwich Street,
De Waterkant, Cape Town
10 Harley Street,
London W1G 9PF